{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:40:44Z","timestamp":1793835644092,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key R&D Program of China","award":["2019YFC1315701"],"award-info":[{"award-number":["2019YFC1315701"]}]},{"name":"the Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center\/Shenzhen Cancer Hospital Research Project","award":["SZ2020ZD004"],"award-info":[{"award-number":["SZ2020ZD004"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270633"],"award-info":[{"award-number":["32270633"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for prediction of the immune response limit the clinical application of anti-PD-1 immunotherapy. Our recent work showed that a combination of low-dose decitabine and PD-1-ab significantly improved the complete response (CR) rate of cHL patients from 32 to 71%, which indicates that there is a significant correlation between epigenetic regulation and the clinical response to immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited two groups of Hodgkin lymphoma patients who were treated with anti-PD-1 and DAC+anti-PD-1. CD8+\u2009T cells were isolated from the patients' peripheral blood, DNA methylation was analyzed by EPIC, the expression profile was analyzed by RNA-seq, and multigroup analysis was performed with IPA and GSEA functional annotations. We explored the effect of DAC on the function of CD8+\u2009T cells in the blood, spleen, tumor and lymph nodes using a mouse model. Furthermore, we explored the function of Tils in the tumor microenvironment. Then, we constructed Runx3-knockout mice to confirm the T-cell-specific function of Runx3 in CD8+\u2009T cells and analyzed various subtypes of T cells and cytokines using mass cytometry (CyTOF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Multiomics analysis identified that DNA methylation reprogramming of\u00a0Runx3 was a crucial mediator of CD8+\u2009T-cell function. Multiomics data showed that reversal of methylation of the Runx3 promoter promoted the infiltration of CD8+\u2009TILs and mitigated the exhaustion of CD8+\u2009T cells. Furthermore, experiments on tissue-specific Runx3-knockout mice showed that Runx3 deficiency reduced CD8+\u2009T infiltration and the differentiation of effector T and memory T cells. Furthermore, Runx3 deficiency significantly decreased CCR3 and CCR5 levels. Immunotherapy experiments in Runx3 conditional knockout\u00a0mice showed that DAC could not reverse the resistance of anti-PD-1 in the absence of Runx3. Moreover, both our clinical data and data from TISIDB showed that Runx3 could be a potential biomarker for immunotherapy to predict the clinical response rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We demonstrate that the DNA methylation of Runx3 plays a critical role in CD8+\u2009T-cell infiltration and differentiation during decitabine-primed PD-1-ab immunotherapy, which provides a supporting mechanism for the essential role of epiregulation in immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-023-01768-0","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T03:34:00Z","timestamp":1684208040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Epigenetic reprogramming of Runx3 reinforces CD8\u2009+\u2009T-cell function and improves the clinical response to immunotherapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Zongzhi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"1768_CR1","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","volume":"37","author":"J Nie","year":"2019","unstructured":"Nie J, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma. J Clin Oncol. 2019;37:1479\u201389.","journal-title":"J Clin Oncol"},{"key":"1768_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12:409.","journal-title":"Nat Commun"},{"key":"1768_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, et al. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973\u201388.","journal-title":"Immunity"},{"key":"1768_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, et al. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"1768_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41422-019-0184-1","volume":"29","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019;29:609\u201327.","journal-title":"Cell Res"},{"key":"1768_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212\u20138.","journal-title":"Nat Immunol"},{"key":"1768_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"1768_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2022","unstructured":"Dong H, et al. Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2022;8:793\u2013800.","journal-title":"Nat Med"},{"key":"1768_CR9","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cancers11101472","volume":"11","author":"T Christofi","year":"2019","unstructured":"Christofi T, et al. Current perspectives in cancer immunotherapy. Cancers. 2019;11:1472.","journal-title":"Cancers"},{"key":"1768_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183:347\u201362 e24.","journal-title":"Cell"},{"key":"1768_CR11","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"1768_CR12","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","volume":"26","author":"FZ Cader","year":"2020","unstructured":"Cader FZ, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020;26:1468\u201379.","journal-title":"Nat Med"},{"key":"1768_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrclinonc.2014.221","volume":"12","author":"A Errico","year":"2015","unstructured":"Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol. 2015;12:63.","journal-title":"Nat Rev Clin Oncol"},{"key":"1768_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nature24759","volume":"552","author":"A Ludin","year":"2017","unstructured":"Ludin A, Zon LI. Cancer immunotherapy: the dark side of PD-1 receptor inhibition. Nature. 2017;552:41\u20132.","journal-title":"Nature"},{"key":"1768_CR15","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020;26:1557\u201363.","journal-title":"Nat Med"},{"key":"1768_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920\u20138.","journal-title":"Nat Med"},{"key":"1768_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fphar.2019.00387","volume":"10","author":"H Zhou","year":"2019","unstructured":"Zhou H, et al. Safety and efficacy of anti-PD-1 monoclonal antibodies in patients with relapsed or refractory lymphoma: a meta-analysis of prospective clinic trails. Front Pharmacol. 2019;10:387.","journal-title":"Front Pharmacol"},{"key":"1768_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"1768_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nm.4489","volume":"24","author":"S Goswami","year":"2018","unstructured":"Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med. 2018;24:123\u20134.","journal-title":"Nat Med"},{"key":"1768_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","volume":"24","author":"C Krieg","year":"2018","unstructured":"Krieg C, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24:144\u201353.","journal-title":"Nat Med"},{"key":"1768_CR21","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.","journal-title":"Science"},{"key":"1768_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.aam7304","volume":"355","author":"MA Dawson","year":"2017","unstructured":"Dawson MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science. 2017;355:1147\u201352.","journal-title":"Science"},{"key":"1768_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.cell.2020.10.045","volume":"183","author":"L Jiang","year":"2020","unstructured":"Jiang L, et al. Direct tumor killing and immunotherapy through anti-serpinB9 therapy. Cell. 2020;183:1219\u201333 e18.","journal-title":"Cell"},{"key":"1768_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.molcel.2020.04.023","volume":"78","author":"VK Wimalasena","year":"2020","unstructured":"Wimalasena VK, et al. Using chemical epigenetics to target cancer. Mol Cell. 2020;78:1086\u201395.","journal-title":"Mol Cell"},{"key":"1768_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2018.30","volume":"15","author":"M Widschwendter","year":"2018","unstructured":"Widschwendter M, et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2018;15:292\u2013309.","journal-title":"Nat Rev Clin Oncol"},{"key":"1768_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","volume":"20","author":"KP Bhat","year":"2021","unstructured":"Bhat KP, et al. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021;20:265\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"1768_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan O, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571:211\u20138.","journal-title":"Nature"},{"key":"1768_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.immuni.2006.03.007","volume":"24","author":"GR Lee","year":"2006","unstructured":"Lee GR, et al. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity. 2006;24:369\u201379.","journal-title":"Immunity"},{"key":"1768_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nri2991","volume":"11","author":"H Cedar","year":"2011","unstructured":"Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev Immunol. 2011;11:478\u201388.","journal-title":"Nat Rev Immunol"},{"key":"1768_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim HE, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017;170:142\u201357 e19.","journal-title":"Cell"},{"key":"1768_CR31","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","volume":"11","author":"S De Biasi","year":"2020","unstructured":"De Biasi S, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11:3434.","journal-title":"Nat Commun"},{"key":"1768_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, et al. Defining \u2018T cell exhaustion.\u2019 Nat Rev Immunol. 2019;19:665\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1768_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian Y, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585:277\u201382.","journal-title":"Nature"},{"key":"1768_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","volume":"25","author":"C Segovia","year":"2019","unstructured":"Segovia C, et al. Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25:1073\u201381.","journal-title":"Nat Med"},{"key":"1768_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41586-019-1411-0","volume":"571","author":"G Cavalli","year":"2019","unstructured":"Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. Nature. 2019;571:489\u201399.","journal-title":"Nature"},{"key":"1768_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1056\/NEJMc1805989","volume":"379","author":"AJ Stonestrom","year":"2018","unstructured":"Stonestrom AJ. The key role of epigenetics in human disease. N Engl J Med. 2018;379:400.","journal-title":"N Engl J Med"},{"key":"1768_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41557-020-0471-y","volume":"12","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Kutateladze TG. Exploring epigenetics with chemical tools. Nat Chem. 2020;12:506\u20138.","journal-title":"Nat Chem"},{"key":"1768_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/542406a","volume":"542","author":"C Willyard","year":"2017","unstructured":"Willyard C. An epigenetics gold rush: new controls for gene expression. Nature. 2017;542:406\u20138.","journal-title":"Nature"},{"key":"1768_CR39","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1016\/S1470-2045(18)30824-6","volume":"19","author":"M Das","year":"2018","unstructured":"Das M. Venetoclax with decitabine or azacitidine for AML. Lancet Oncol. 2018;19:e672.","journal-title":"Lancet Oncol"},{"key":"1768_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/ph5080875","volume":"5","author":"RL Momparler","year":"2012","unstructured":"Momparler RL. A perspective on the comparative antileukemic activity of 5-Aza-2\u2019-deoxycytidine (Decitabine) and 5-azacytidine (Vidaza). Pharmaceuticals (Basel). 2012;5:875\u201381.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1768_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.19.01053","volume":"38","author":"M Lubbert","year":"2020","unstructured":"Lubbert M, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 x 2, phase II trial. J Clin Oncol. 2020;38:257\u201370.","journal-title":"J Clin Oncol"},{"key":"1768_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia. 2021;35:62\u201374.","journal-title":"Leukemia"},{"key":"1768_CR43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMp1615069","volume":"376","author":"JS Welch","year":"2017","unstructured":"Welch JS, Petti AA, Ley TJ. Decitabine in TP53-mutated AML. N Engl J Med. 2017;376:797\u20138.","journal-title":"N Engl J Med"},{"key":"1768_CR44","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, et al. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020;136:674\u201383.","journal-title":"Blood"},{"key":"1768_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nrc2948","volume":"10","author":"M Swami","year":"2010","unstructured":"Swami M. Epigenetics: demethylation links cell fate and cancer. Nat Rev Cancer. 2010;10:740.","journal-title":"Nat Rev Cancer"},{"key":"1768_CR46","doi-asserted-by":"publisher","first-page":"13145","DOI":"10.1096\/fj.201900310R","volume":"J33","author":"Y Wang","year":"2019","unstructured":"Wang Y, et al. Methylation-dependent transcriptional repression of Runx3 by KCNQ1OT1 regulates mouse cardiac microvascular endothelial cell viability and inflammatory response following myocardial infarction. FASEB. 2019;J33:13145\u201360.","journal-title":"FASEB"},{"key":"1768_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/0008-5472.CAN-17-1178","volume":"78","author":"V Krishnan","year":"2018","unstructured":"Krishnan V, et al. TGFbeta promotes genomic instability after loss of Runx3. Cancer Res. 2018;78:88\u2013102.","journal-title":"Cancer Res"},{"key":"1768_CR48","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.immuni.2018.03.028","volume":"48","author":"D Wang","year":"2018","unstructured":"Wang D, et al. The transcription factor Runx3 establishes chromatin accessibility of cis-regulatory landscapes that drive memory cytotoxic t lymphocyte formation. Immunity. 2018;48:659\u201374 e6.","journal-title":"Immunity"},{"key":"1768_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature24993","volume":"552","author":"JJ Milner","year":"2017","unstructured":"Milner JJ, et al. Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours. Nature. 2017;552:253\u20137.","journal-title":"Nature"},{"key":"1768_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0092-8674(02)01111-X","volume":"111","author":"I Taniuchi","year":"2002","unstructured":"Taniuchi I, et al. Differential requirements for RUNX proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002;111:621\u201333.","journal-title":"Cell"},{"key":"1768_CR51","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1073\/pnas.1232420100","volume":"100","author":"E Woolf","year":"2003","unstructured":"Woolf E, et al. Runx3 and RUNX1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA. 2003;100:7731\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1768_CR52","doi-asserted-by":"publisher","first-page":"16016","DOI":"10.1073\/pnas.0407180101","volume":"101","author":"O Brenner","year":"2004","unstructured":"Brenner O, et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA. 2004;101:16016\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1768_CR53","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1349-7006.2003.tb01425.x","volume":"94","author":"K Miyazono","year":"2003","unstructured":"Miyazono K, et al. Regulation of TGF-\u03b2 signaling and its roles in progression of tumors. Cancer Sci. 2003;94:230\u20134.","journal-title":"Cancer Sci"},{"key":"1768_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/sj.emboj.7600085","volume":"23","author":"O Faninaru","year":"2004","unstructured":"Faninaru O, et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J. 2004;23:969\u201379.","journal-title":"EMBO J"},{"issue":"18","key":"1768_CR55","doi-asserted-by":"publisher","first-page":"9804","DOI":"10.3390\/ijms22189804","volume":"22","author":"P Bule","year":"2021","unstructured":"Bule P, et al. Chemokine-directed tumor microenvironment modulation in cancer immunotherapy. Int J Mol Sci. 2021;22(18):9804.","journal-title":"Int J Mol Sci"},{"key":"1768_CR56","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/genes13091568","volume":"13","author":"E Dybska","year":"2022","unstructured":"Dybska E, et al. Methylation of Runx3 Promoter 2 in the Whole Blood of Children with Ulcerative Colitis. Genes. 2022;13:1568.","journal-title":"Genes"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01768-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T03:41:01Z","timestamp":1684208461000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1768"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01768-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and all samples were collected from Chinese PLA General Hospital (Beijing, China) with the informed consent of the patients, and approved by the Medical Ethics Committee of Chinese PLA General Hospital Chinese PLA Medical School (protocol code S2016-127\u201301 approved 24 November 2016), The animal experiments were approved by the Medical Ethics Committee of Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center (protocol code 2022\u201324 approved 23 March 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree with the content of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}